Indeed, this is further supported by evidence that statins that are used to lower cholesterol might be protective in prostate cancer [125], yet levels of ApoE were found to be quite different for APOE ε3 and ε2 carriers compared to APOE ε4 carriers who incidentally displayed more modest changes in various cholesterol targets (total cholesterol, LDL, and HDL) compared to the APOE ε4 non-carriers [126]. This evidence concerns the gene APOE and prostate carcinoma.